Holen Sie sich die Stockscreener-App
28.82
6.78%
1.83
Handel nachbörslich:
28.66
-0.16
-0.56%
Schlusskurs vom Vortag:
$26.99
Offen:
$27.67
24-Stunden-Volumen:
58.72M
Relative Volume:
1.68
Marktkapitalisierung:
$6.57B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
55.20
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+48.33%
1M Leistung:
+15.37%
6M Leistung:
-42.11%
1J Leistung:
+5.84%
1-Tages-Spanne:
$27.40
$29.78
1-Wochen-Bereich:
$19.30
$29.78
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
28.82 | 6.15B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.17B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 50.06B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 42.70B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 36.40B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.44B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Health, Inc. (NYSE:HIMS) Sees Large Drop in Short Interest - MarketBeat
HIMS Receives Upgrade Amid Positive Regulatory Outlook - GuruFocus
7 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Surge - Yahoo Finance
SA analyst upgrades/downgrades: NVDA, VZ, MRVL, HIMS - Seeking Alpha
Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum - International Business Times Australia
+7.34% for Hims & Hers Health stock as FDA eyes peptide drug policy change - Traders Union
What's Going On With Hims & Hers Shares - Benzinga
Here’s How Cedar Grove Capital Management Benefitted from Its Short Position in Hims & Hers Health (HIMS) - Yahoo Finance
Hims & Hers stock rises 14% as FDA schedules peptide compounding review - Yahoo Finance
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Hims Hers Health Surprise Signals New Healthcare Momentum Shift Ahead - Kalkine Media
HIMS Stock's Rally May Have Plenty Of Room Left: FDA Opens Door To Testosterone Therapy - Stocktwits
HIMS Stock Closes Another Day In The Green — But Retail Sees More Upside - Stocktwits
Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s - AOL.com
HIMS Stock Rises 7% on Potential FDA Regulatory Changes - GuruFocus
Eli Lilly's Oral Drug Clears CV Test, Hims Surges 14% - Gotrade
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies - Yahoo Finance
These Stocks Are Today’s Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More - Barron's
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions - TechStock²
What's Going On With Hims & Hers Stock Thursday - GuruFocus
RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here? - Barchart
Best Healthcare Stocks To Watch NowApril 16th - MarketBeat
Hims & Hers shares jump as FDA begins review of restricted peptide compounds - Yahoo! Finance Canada
HIMS: Positive Regulatory Developments Boost Stock Outlook - GuruFocus
Leerink reiterates Hims and Hers stock rating on peptide outlook - Investing.com
Hims & Hers Stock: How RFK Jr Loosened Peptide Regulations and Sent Shares Higher - Barron's
HIMS Stock Surges as FDA Plans Review on Peptide Compounding - GuruFocus
Hims rises as FDA considers broader peptides access; analysts see long-term win - Reuters
Hims & Hers (HIMS) Stock; Climbs 8% as FDA Peptide Review Sparks Expansion Hopes - CoinCentral
Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides - Yahoo Finance
Hims stock gains as FDA reviews peptides, Voyager secures NASA contract - Yahoo Finance
Hims & Hers extends gains on optimism over FDA peptide - Yahoo Finance
BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming? - Yahoo Finance
Biggest stock movers Thursday: AEHR, ABT, HOOD, COIN, and more (NYSE:HIMS) - Seeking Alpha
Market movers: Hims & Hers, Abbott Laboratories, QVC… - Proactive financial news
HIMS Stock Surges on FDA's Potential Regulatory Changes - GuruFocus
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell? - Yahoo Finance
Hims & Hers stock rises as FDA schedules peptide review - Yahoo Finance
HIMS Maintained by B of A Securities -- Price Target Raised to $25 - GuruFocus
Bank of America Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price - MarketBeat
FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade) - Seeking Alpha
Hims & Hers (HIMS) Stock Jumps 13% as FDA Opens Door to Peptide Review - CoinCentral
HIMS Shares Surge 11% on FDA Regulatory News - GuruFocus
Hims & Hers (HIMS) Shares Surge on FDA Peptide Regulation Update - GuruFocus
Why Is Hims & Hers Stock Soaring After FDA's Announcment? - Benzinga
Hims & Hers on track to extend gains as RFK Jr. seeks to loosen peptide regulations (HIMS:NYSE) - Seeking Alpha
Hims Jumps as RFK Jr. Seeks to Loosen Peptide Regulations - The Business of Fashion
Hims & Hers shares rise 11% on FDA peptide restriction changes - Investing.com
Hims & Hers Providers Can't Duck Suit Over Student's Suicide - Law360
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
6.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):